Date:12/21/2011

tations.  For example, there can be no assurance that that company will be successful in jointly developing customized nutritional supplements, pharmaceuticals or medical foods; that clinical studies will be regarded as sufficient substantiation for corresponding product claims or that the products will be accepted as being sufficiently safe, improved or cost-effective compared to other products; that the products can be successfully developed and commercially successful or will effectively enhance our businesses; that results or trends observed in clinical studies or other observations will be reproduced in subsequent studies or in broader use; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that the Food and Drug Administration, the Federal Trade Commission or other regulatory agencies will not introduce additional or more restrictive regulations covering naturally-derived products; that our in-house or external product commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our co-development and strategic licensing arrangements will successfully and in a timely manner lead to the development, formulation, manufacture and licensing of products; or that these or any other third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of biologics and in the development and commercialization of new products, the conduct of human clinical trials and other product development efforts, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory
'/>"/>

SOURCE Cardium Therapeutics Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Cardium to Present at the Rodman & Renshaw Annual Healthcare Investment Conference
2. Cardium Provides Update on Exchange Listing and Related Business Matters
3. Cardium to Present at Southern California Investor Conference
4. Cardium Announces Receipt of $1.1 Million in Funds from Philips Acquisition of Innercool Therapies
5. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
6. Cardium Provides Update on Excellagen 510(K) Registration and Commercialization Plans
7. Cardium Reports on Transdel Transaction
8. Cardium Announces Market Introduction of New Alena™ Clinical Strength Carb Blocker to Expand the MedPodium Healthy Lifestyle Product Line
9. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
10. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
11. Cardium Presents First Quarter 2011 Financial Results and Reports on Near-Term Milestones